A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Conference Paper uri icon

authors

  • Luke, Jason J
  • Patel, Manish R
  • Hamilton, Erika Paige
  • Chmielowski, Bartosz
  • Ulahannan, Susanna Varkey
  • Kindler, Hedy L
  • Bahadur, Shakeela Wazeen
  • Clingan, Philip R
  • Mallesara, Girish
  • Weickhardt, Andrew James
  • Currence, Scott
  • Xu, Linzhi
  • Kaul, Sanjeev
  • Chen, Francine
  • Moore, Paul A
  • Bonvini, Ezio
  • Sumrow, Brad
  • Blumenschein, George

publication date

  • May 20, 2020